ORKA Oruka Therapeutics Inc.

Price (delayed)

$108.12

Market cap

$7.16B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.03

Enterprise value

$6.89B

?
Relative Growth: Rel. Growth: 0
Relative Strength: Rel. Strength: 99
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 8

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator for the treatment ...

Highlights
The company's equity has surged by 129% QoQ
The company's quick ratio has surged by 63% QoQ and by 40% YoY
The company's debt rose by 41% QoQ and by 9% YoY
Oruka Therapeutics's net income has decreased by 33% YoY and by 14% QoQ

Key stats

What are the main financial stats of ORKA

ORKA stock price

How has the Oruka Therapeutics stock price performed over time
Intraday
0.67%
1 week
9.86%
1 month
27.86%
1 year
605.28%
YTD
256.71%
QTD
13.61%

Financial performance

How have Oruka Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$155.08M
Net income
-$132.89M
Gross margin
N/A
Net margin
N/A
ORKA's operating income is down by 37% year-on-year and by 16% since the previous quarter
Oruka Therapeutics's net income has decreased by 33% YoY and by 14% QoQ

Price vs fundamentals

How does ORKA's price correlate with its fundamentals

Growth

What is Oruka Therapeutics's growth rate over time

Valuation

What is Oruka Therapeutics stock price valuation
P/E
N/A
P/B
5.85
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Oruka Therapeutics's EPS has decreased by 4.6% from the previous quarter
The company's equity has surged by 129% QoQ
ORKA's price to book (P/B) is 99% lower than its 5-year quarterly average of 1154.2 but 58% higher than its last 4 quarters average of 3.7

Efficiency

How efficient is Oruka Therapeutics business performance
Oruka Therapeutics's return on invested capital has increased by 45% YoY and by 16% QoQ
The return on equity has grown by 25% year-on-year and by 20% since the previous quarter
Oruka Therapeutics's return on assets has increased by 22% YoY and by 20% QoQ

Dividends

What is ORKA's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did Oruka Therapeutics financials performed over time
The company's total assets has surged by 126% QoQ
Oruka Therapeutics's total liabilities has surged by 80% YoY and by 40% QoQ
The company's debt is 100% lower than its equity
The company's equity has surged by 129% QoQ
The company's debt to equity has shrunk by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.